Moderna R&D day: $1 billion in cost cuts, 10 product launches
Sep 12, 2024 · Moderna on Thursday said it plans to cut around $1.1 billion in expenses by 2027 and win approvals for several new products as it charts a path forward after the rapid decline …
Moderna, Inc. (MRNA) Latest Stock News & Headlines - Yahoo …
Get the latest Moderna, Inc. (MRNA) stock news and headlines to help you in your trading and investing decisions.
Moderna stock forfeits gains as first US bird flu death puts vaccine ...
2 days ago · Moderna’s revenue fell 64% to just below $7 billion in 2023 (far below the $18.5 billion in sales reported in 2020), and the company reported a loss of roughly $12 per share.
News Details - Moderna
Mar 26, 2024 · mRNA-1283 induced a more robust immune response compared to Spikevax® COVID-19 vaccine, mRNA-1273.222. Next-generation mRNA vaccine design offers the potential of longer shelf life and storage advantages, and paves the way for combination vaccine against influenza and COVID-19, mRNA-1083.
Moderna CEO confronts challenges for RSV, COVID businesses
4 days ago · Moderna’s stock price has dropped about 60% in the past 12 months. Facing this set of challenges, Moderna in September laid out a plan to cut annual R&D spending by more than 20%, or $1.1 ...
News Details - Moderna
Sep 11, 2023 · Moderna's updated COVID-19 vaccine contains spike proteins for the XBB.1.5 sublineage of SARS-CoV-2 to help prevent COVID-19 in individuals 6 months of age and older. With the U.S. FDA's decision, Moderna will begin shipping doses to vaccination sites across the U.S., with updated vaccines expected to be available in the coming days.
News Details - Moderna
Jun 10, 2024 · CAMBRIDGE, MA / ACCESSWIRE / June 10, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that its Phase 3 trial of mRNA-1083, an investigational combination vaccine against influenza and COVID-19, has met its primary endpoints, eliciting a higher immune response than the licensed comparator vaccines used in the trial.
Moderna forecasts lower sales next year, shares near four-year low
Sep 12, 2024 · Moderna pushed back its break-even goal by two years on Thursday as it delayed the timeline for developing several key products and predicted 2025 sales below its forecast for the current year,...
Moderna reports surprise profit on higher-than-expected COVID …
Nov 7, 2024 · Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its COVID-19 vaccine, even with low revenue from its new respiratory...
Moderna news - Today’s latest updates - CBS News
Feb 19, 2023 · Drug manufacturer Moderna says its COVID-19 vaccine could cost as much as $130 per dose once it switches to commercial distribution. The Biden administration announced last year that the federal...
- Some results have been removed